Neurocrine Biosciencesvs.United Therapeutics
NBIX vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
United Therapeutics is about 1.3× larger than Neurocrine Biosciences by market cap; United Therapeutics trades at the lower P/E (18.0 vs 26.4); year to date, Neurocrine Biosciences leads (+24.9% vs +12.3%).
Side by side
| NBIX | UTHR | |
|---|---|---|
| Market cap | $17.7B | $23.2B |
| Price | $177.11 | $547.06 |
| Today | −1.9% | −1.0% |
| Return YTD | +24.9% | +12.3% |
| Return 1Y | +31.3% | +82.3% |
| P/E | 26.4 | 18.0 |
| P/S | 5.7 | 7.3 |
| P/B | 5.2 | 3.9 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Neurocrine BiosciencesNBIX
Biopharma focused on neurological and endocrine diseases (Ingrezza).
Full NBIX profile →United TherapeuticsUTHR
Biopharma in pulmonary hypertension and organ manufacturing (xenotransplantation).
Full UTHR profile →More comparisons in Biotech & innovation
See where NBIX and UTHR sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →